Hibiki Akashi1, Rikio Suzuki1, Hidetsugu Kawai1, Jun Amaki1, Ryujiro Hara2, Akifumi Ichiki3, Hiroki Numata4, Yasuyuki Aoyama5, Hiromichi Murayama4, Kei Tazume2, Tamotsu Sasao3, Yoshiaki Ohbayashi5, Yukari Shirasugi1, Yoshiaki Ogawa1, Hiroshi Kawada1, Kiyoshi Ando1 (1.Hematolgy/Oncology, Tokai Univ., Kanagawa, Japan, 2.Department of Hematology, Isehara Kyodo Hospital, Isehara Japan, 3.Department of Hematology, Ozawa Hospital, Odawara, Japan, 4.Department of Hematology, Ebina General Hospital, Ebina, Japan, 5.Department of Hematology, Hiratsuka Kyosai Hospital, Hiratsuka, Japan)
Session information
Oral Session
Oral Session 3-7B Multiple Myeloma: Clinical Studies (2)
Sun. Oct 13, 2019 10:10 AM - 11:10 AM No.7 (Tokyo International Forum, 5F Hall D5)
Chair: Hirohiko Shibayama (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
Yuichiro Inagaki, Kenta Motegi, Fumiya Ohara, Hiroya Wakabayashi, Hirofumi Yokota, Shihomi Kuwano, Yuki Takeuchi, Hitomi Sawa, Kotaro Miyao, Masashi Sawa (Anjo Kosei Hospital)
Yuichiro Inagaki, Kenta Motegi, Fumiya Ohara, Hiroya Wakabayashi, Hirofumi Yokota, Shihomi Kuwano, Yuki Takeuchi, Hitomi Sawa, Kotaro Miyao, Masashi Sawa (Anjo Kosei Hospital)
Yasuhiko Miyata1, Manami Takizawa1, Masayuki Takagishi2, Haruyoshi Kawai2, Akiko Fujino3, Tsutomu Yajima4, Eriko Arita5, Kentaro Enjo1 (1.Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan, 2.Safety Risk Management Division, Janssen Pharma K. K., 3.Japan Safety & Surveillance Division, Janssen Pharma K. K., 4.Biostatistics, Janssen Pharma K. K., 5.Quantitative Sciences Division, Janssen Pharma K. K.)
Kazutaka Sunami, Takashi Moriyama, Hiroyuki Murakami, Tatsunori Ishikawa, Takanori Yoshioka, Masanori Makita (Dept. of Hematol., NHO Okayama Medical Center)
Katsuya Fujimoto, Masahiro Chiba, Sachiko Suzuki, Mitsutoshi Kurosawa (Department of Hematology, Hokkaido Cancer Center, Sapporo, Japan)